Sosei Group Corp. decided to withdraw the nomination of Michael Hayden as an external director.
The appointment had been scheduled for a vote at the company's annual general meeting June 22.
Hayden previously was the global research and development president and chief scientific officer at Teva Pharmaceutical Industries Ltd.
He was nominated, along with Kuniaki Kaga and David Roblin, to provide oversight of the company's research and development pipeline, among other duties.
